{"id":"W2984791646","doi":"10.1182/blood-2020-141087","title":"A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of New Brunswick; Thunder Bay Regional Research Institute; Dalhousie University; Princess Margaret Cancer Centre; University of Calgary; Thunder Bay Regional Health Sciences Centre; University Health Network; Ottawa Hospital; CancerCare Manitoba; McGill University Health Centre; Juravinski Cancer Centre; Saint John Regional Hospital; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Daratumumab; Dexamethasone; Internal medicine; Cyclophosphamide; Clinical endpoint; Regimen; Multiple myeloma; Progressive disease; Refractory (planetary science); Oncology; Surgery; Gastroenterology; Urology; Clinical trial; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003297305,0.003372969,0.004223729,0.0008034257,0.0008214971,0.001915555,0.001374862,0.002286721,0.007708767],"category_scores_gemma":[0.002399049,0.001772711,0.002004504,0.0007388502,0.003073314,0.002221145,0.0007620578,0.00532405,0.001808601],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001032145,"about_ca_system_score_gemma":0.002943859,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001134302,"about_ca_topic_score_gemma":0.002104136,"domain_scores_codex":[0.9987557,0.0006023488,0.00007171654,0.0002429691,0.00009888034,0.0002283346],"domain_scores_gemma":[0.9981128,0.0004350371,0.0002952077,0.000173453,0.0001038778,0.000879607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.948675,0.03572423,0.0007202935,0.0002350709,0.0002860205,0.00005512713,0.00008292532,0.0003866421,0.004182775,0.000114734,0.0006699563,0.008867256],"study_design_scores_gemma":[0.8792679,0.1186773,0.0007291374,0.000008146284,0.0001141666,0.00002550354,0.00001809096,0.0002644036,0.0003109415,0.0001084989,0.0004624086,0.00001345118],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9788632,0.00180462,0.0009659355,0.001076025,0.0007972218,0.01266701,0.001423782,0.0001737811,0.002228449],"genre_scores_gemma":[0.9653655,0.002700511,0.00358748,0.002672923,0.001069066,0.01544461,0.002054468,0.00005856454,0.007046862],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007708767,"threshold_uncertainty_score":0.02578837,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03769247981951125,"score_gpt":0.3218313031854524,"score_spread":0.2841388233659412,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}